FDB (First Databank) vs Synapse Medicine (2026)
Two medication knowledge companies on opposite sides of the Atlantic with opposite theories about where the intelligence belongs. FDB supplies the drug content sitting under most American prescribing systems, so its databases are the baseline that every interaction alert in that market is built on, and it licenses that content into customers' own systems. Synapse puts machine learning upstream of the clinical decision instead, reading and classifying medication information rather than generating recommendations, and distributes through other software as well as directly into more than a hundred hospitals. The design distinction is the useful part: one company owns the content everyone relies on, which creates a concentration exposure where a single gap propagates everywhere, and the other deliberately keeps the model out of the recommendation.
- Its drug knowledge sits underneath most prescribing systems in the United States, so its content is the baseline against which any additional layer is measured.
- The licensing architecture is clean by design, with content embedded in customers' own systems, which places hosting and processing questions with the customer.
- Its own newer products are framed conservatively, with the prescription agent producing orders explicitly for physician review.
- The machine learning sits upstream of the clinical decision rather than inside it, reading and classifying medication information rather than generating a recommendation, which is a deliberate and defensible design.
- The method and the sources are both named, and distribution runs through other software as well as direct deployment across more than a hundred hospitals.
- Medication reconciliation is the practical problem in most European hospitals, and this is built for it rather than adapted to it.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. FDB (First Databank) and Synapse Medicine are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | FDB (First Databank) | Synapse Medicine |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | Not recorded | 2017 |
| Headquarters | South San Francisco, California, United States | Bordeaux, France |
| Website | fdbhealth.com | synapse-medicine.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards FDB (First Databank) its top capability grade on EHR and Interoperability Depth. Set against Synapse Medicine, FDB (First Databank) grades higher on EHR and Interoperability Depth. Its thinnest published disclosure sits on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index records no top capability grade for Synapse Medicine on any axis it scores. Set against FDB (First Databank), Synapse Medicine grades higher on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. Its thinnest published disclosure sits on Security Certifications and Trust Center, AI Governance and Bias Disclosure and Commercial Transparency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose FDB (First Databank) or Synapse Medicine?
On the axes where the AI Health Index separates them, FDB (First Databank) grades higher on EHR and Interoperability Depth, and Synapse Medicine grades higher on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. Synapse Medicine leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do FDB (First Databank) and Synapse Medicine differ most?
The widest separation the AI Health Index records between FDB (First Databank) and Synapse Medicine is on AI Centrality, where FDB (First Databank) grades D and Synapse Medicine grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do FDB (First Databank) and Synapse Medicine grade the same?
The AI Health Index grades FDB (First Databank) and Synapse Medicine the same on several axes, including Autonomy and Oversight Model, Model and Technology Transparency and Clinical and Operational Evidence. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have FDB (First Databank) and Synapse Medicine not disclosed?
At the last review, at least one of FDB (First Databank) and Synapse Medicine published thin or absent detail on several axes, including AI Centrality, Model Supply Chain Disclosure and HIPAA and BAA Posture. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The two operate under different regimes and neither transfers automatically: one supplies content into United States systems where the obligation sits with the software vendors embedding it, the other is European and graded against the frameworks that govern it there. Neither publishes a security attestation, and neither publishes a bias assessment or performance reporting by patient characteristic.
The concentration exposure applies to the content supplier specifically: when one curated knowledge base underlies most medication decisions in a country, a gap propagates everywhere at once, which is a different governance question from bias.